Prophylaxis in developed and in emerging countries.
The significant progress made in recent years in the safety and efficacy of both plasma-derived and recombinant factor concentrates has allowed treatment programmes to be developed that go beyond the simply curative or the treatment of the consequences of the disease (episodic or on-demand treatment), enabling the criteria of preventative medicine to be applied to congenital bleeding disorders. The aim of these programmes is to achieve constant, minimum levels of factor in patients above 1 or 2%, thereby converting severe haemophilia into moderate haemophilia.
Tusell
J
J
Hospital Vall d'Hebron, Barcelona, Spain, Academia Nacional de Medicina, Buenos Aires, Argentina. jtusell.hmi@cs.vhebron.es
Pérez-Bianco
R
R
D003906:Developing Countries; D006395:Hemarthrosis / Q000517:prevention & control; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans